The antihypertensive effect of Eucommia leaf extract comes from its three core active ingredients, which are efficiently enriched and synergistic through supercritical CO2 extraction technology:
1. Chlorogenic acid (≥15%)
Target: inhibit angiotensin converting enzyme (ACE), block the production of vasoconstrictor factor AngⅡ; activate endothelial nitric oxide synthase (eNOS), increase NO release, and dilate blood vessels.
Clinical data: Single-ingredient intervention can reduce systolic blood pressure by 8-12%, and the efficiency of combined use with conventional antihypertensive drugs is increased by more than 50%.
2. Geniposide
Regulatory pathway: Accurately regulate the renin-angiotensin system (RAS), balance the blood pressure regulation network, and prevent abnormal blood pressure fluctuations.
Core advantage: Significant effect on diastolic blood pressure regulation, clinical trials show that diastolic blood pressure drops by 5-8%.
3. Flavonoids (≥8%)
Protective mechanism: scavenging free radicals, reducing oxidative stress levels, repairing vascular endothelial damage, and improving microcirculatory disorders.
Synergistic value: Combined use with chlorogenic acid can reduce blood pressure fluctuations by 30% and prolong the duration of antihypertensive effects.
1. Multicenter clinical trial at a university in Zhejiang (2023)
Research design: 120 patients with primary hypertension were included and randomly divided into double-blind groups (experimental group: conventional drugs + 200mg/day Eucommia extract).
Key results:
After 8 weeks, the systolic/diastolic blood pressure in the experimental group decreased by 12.4/7.6mmHg, which was 2 times higher than that in the control group (6.2/3.8mmHg) (P<0.01);
24-hour dynamic blood pressure monitoring showed that the nighttime blood pressure fluctuation rate was reduced by 28%.
2. Animal model study at a university in Japan (2022)
Experimental subjects: spontaneously hypertensive rats (SHR), with continuous administration for 4 weeks.
Breakthrough discovery:
Blood pressure dropped from 185/125mmHg to 155/105mmHg, close to normal levels;
Endothelial eNOS activity increased by 40%, confirming the endothelial function repair mechanism.
1. Supercritical CO2 extraction process
Technical barriers:
Purity breakthrough: Chlorogenic acid purity ≥ 98% (traditional process is only 80-85%), active ingredient yield 95% (industry average <75%);
Safety guarantee: zero solvent residue, passed FDA GRAS certification, and met the standards of pharmaceutical-grade raw materials.
2. Dosage form development and scenario adaptation
Scientific research direction: Deepen the research on multi-component synergistic mechanisms and develop targeted preparations for secondary hypertension;
Industrial layout: Jointly establish a "medicine and food homology" product matrix with medical institutions to cover the entire cycle of prevention-treatment-rehabilitation;
Compliance path: Promote international pharmacopoeia standard certification (such as USP, EP) to accelerate global market access.
The scientific verification and technological innovation of Eucommia ulmoides’ antihypertensive function provide a complete paradigm from laboratory to industry for the development of natural medicines, which has both clinical value and commercial potential.
